Studies and Resources
Perfect Timing for a Natural
Breakthrough
Science Studies PDF
TriGLP Bioactive
Peptide Complex
Executive Summary for
Physician Review Overview
TriGLP
is a
proprietary, patent-protected bioactive
peptide complex derived from
enzymatically hydrolyzed Atlantic salmon
protein. It is designed to support
metabolic efficiency, fat-specific
weight reduction, preservation of lean
muscle mass, gut integrity, and energy
metabolism, particularly in aging and
metabolically stressed populations.
triGLP is classified as a New Dietary
Ingredient (NDI) in the United States
with self-affirmed GRAS status.
Distinctive
Characteristics
* Unique peptide
fingerprint distinct from over 1,300
commercial hydrolysates
* Bioactive signaling effects beyond
nutritional protein intake
* Rapid absorption and high
bioavailability
* Human-grade Norwegian Atlantic salmon
source
* Non-GMO, additive-free,
antibiotic-free
* Mechanism of Action (Summary)
Preclinical and
mechanistic studies indicate
peptide-mediated modulation of GLP-1,
GIP, and GLP-2 pathways, along with gene
expression changes including
upregulation of HMOX-1 (antioxidant and
gut protection) and FTH1 (iron
metabolism), and downregulation of
ALOX-12 (inflammatory signaling). These
effects appear independent of caloric or
macronutrient contribution.
Human Clinical Findings
Metabolic Health
(Healthy Adults):
7% BMI reduction and ~10% body fat
reduction over 8 weeks with no loss of
body water; improved fasting glucose,
reduced inflammatory markers, and
increased ferritin levels.
Overweight Subjects:
6% BMI reduction over 6 weeks; improved
insulin sensitivity, lipid markers, and
reduced IL-6.
Energy & Vitality:
Improved subjective energy, reduced
oxidative stress, increased
anti-inflammatory IL-10, and improved
morning energy at doses as low as 4
g/day.
Lean Muscle Preservation
In vitro and preclinical
data demonstrate dose-dependent
inhibition of myostatin and activin A,
suggesting preservation of skeletal
muscle mass during weight reduction.
This differentiates triGLP from
pharmacologic GLP-1 agonists commonly
associated with lean mass loss.
Gut Health &
Tolerability
triGLP demonstrated
improved gut structural integrity and
reduced inflammation in preclinical IBD
models. Human data indicate rapid
absorption, improved digestibility, and
minimal gastrointestinal burden compared
to whey protein.
Clinical Relevance &
Conclusion
triGLP represents a
mechanistically distinct bioactive
peptide intervention supporting
fat-specific weight loss, lean muscle
preservation, improved glucose handling,
reduced inflammation, and enhanced
energy metabolism. Available evidence
supports favorable tolerability and
clinical relevance, with further
large-scale trials warranted.
GLP-1–Based
Pharmacotherapy vs triGLP® Bioactive Peptide Complex
One-page clinical comparison (for clinician discussion;
not a substitute for prescribing information).
|
Domain |
GLP-1–Based Pharmacotherapy |
triGLP® Bioactive Peptide Complex |
|
Regulatory status |
Prescription drugs (FDA-approved indications
vary by agent; follow label). |
Dietary supplement ingredient/complex
regulated under dietary supplement framework
(structure/function statements; not for
diagnosis, treatment, cure, or prevention of
disease). |
|
Examples |
GLP-1 receptor agonists (e.g., semaglutide,
liraglutide, dulaglutide). Dual incretin agents
(e.g., tirzepatide [GIP/GLP-1]) are discussed in
the same clinical category but are not
GLP-1-only. |
Proprietary salmon-derived peptide complex
produced via enzymatic hydrolysis. |
|
Primary intended clinical use |
Type 2 diabetes management; some agents
indicated for chronic weight management;
cardiovascular risk reduction varies by agent. |
Support of metabolic efficiency, body
composition, gut integrity, and energy
metabolism (supportive wellness positioning). |
|
Mechanism (high level) |
GLP-1 receptor agonism increases
glucose-dependent insulin secretion, reduces
glucagon, delays gastric emptying, and increases
satiety; some agents include GIP activity. |
Bioactive peptide signaling influencing
incretin-related pathways (GLP-1/GIP/GLP-2) and
gene-expression pathways (antioxidant and
iron-regulatory markers) per preclinical
materials. |
|
Route & dosing |
Typically injectable (weekly or daily); oral
semaglutide exists. Dose titration required to
reduce GI effects. |
Oral powder or drop formats; fixed daily
dosing per manufacturer; no injection. |
|
Efficacy – weight & adiposity |
Clinically meaningful weight loss in many
patients; magnitude varies by agent, dose,
adherence, and lifestyle. |
Small human studies report ~6–7% BMI
reduction over 6–8 weeks driven by fat loss;
larger trials needed. |
|
Glycemia / A1C |
Robust A1C reduction in T2D; low hypoglycemia
risk unless combined with insulin or
sulfonylureas. |
Supportive data suggest improved fasting
glucose and insulin sensitivity; not indicated
for diabetes treatment. |
|
Lean mass considerations |
Lean mass loss may occur, particularly with
rapid weight loss or in older adults. |
In vitro data suggest myostatin/activin A
inhibition and potential lean-mass preservation;
clinical confirmation limited. |
|
Common adverse effects |
Nausea, vomiting, diarrhea or constipation,
abdominal pain; gallbladder disease risk;
pancreatitis signal. |
Generally well tolerated; mild GI sensitivity
possible as with other peptide products. |
|
Key contraindications / warnings |
Agent-specific boxed warnings (e.g., thyroid
C-cell tumors for some GLP-1 RAs); review label. |
Fish/seafood allergy consideration; caution
in pregnancy, lactation, or major comorbidities. |
|
Monitoring |
Weight, BP, glycemic indices, GI tolerance,
renal function if dehydrated. |
Monitor weight, symptoms, and labs as
clinically indicated. |
|
Evidence base |
Large randomized controlled trials with
long-term outcomes. |
Early-stage human studies plus mechanistic
and preclinical data. |
|
Access & cost |
Insurance-dependent access; discontinuation
often leads to weight regain. |
Direct-to-consumer access; cost varies;
easier adherence for injection-averse users. |
Important:
This comparison is informational and does not constitute
medical advice.
|